Quick Answer
Tango Therapeutics, Inc. reported Net Income of -$101.59 million for fiscal year 2025.
Tango Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$101.59M | +22.0% |
| 2024 | -$130.30M | -28.1% |
| 2023 | -$101.74M | +5.9% |
| 2022 | -$108.18M | -85.8% |
| 2021 | -$58.23M | -12.1% |
| 2020 | -$51.97M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $15.88M | +154.5% | +140.9% |
| June 30, 2025 | -$38.85M | -52.1% | +2.6% |
| March 31, 2025 | -$39.88M | -5.2% | -36.7% |
| September 30, 2024 | -$29.17M | -31.0% | -14.2% |
| June 30, 2024 | -$25.55M | -23.4% | +32.6% |
| March 31, 2024 | -$37.91M | -35.4% | -70.3% |
| September 30, 2023 | -$22.26M | +23.4% | -7.5% |
| June 30, 2023 | -$20.71M | +16.7% | +26.1% |
- Tango Therapeutics, Inc. showed an increase of +22.0% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Tango Therapeutics, Inc.’s net income has declined by 95.5% (from -$51.97 million to -$101.59 million).
- The most recent figure is from Tango Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: